Latest market price
72.88
-0.75-1.02%
ALCQT45Alcon Inc.·NYSE
72.88-1.02%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E56.64EPS (ttm)1.30Insider Own—Shs Outstand483.40MPerf Week5.20%
Market Cap35.59BForward P/E18.77EPS next Y3.92Insider Trans—Shs Float481.83MPerf Month15.48%
Enterprise Value39.35BPEG4.11EPS next Q0.89Short Float4.06%Perf Quarter3.72%
Income639.00MP/S3.29EPS this Y13.49%Short Ratio10.77Perf Half Y0.20%
Sales10.81BP/B1.65EPS next Y12.90%ROA2.06%Short Interest19.55MPerf YTD-6.57%
Book/sh44.68P/C24.43EPS next 5Y13.77%ROE2.91%52W High87.64 -16.84%Perf Year-0.85%
Cash/sh3.01P/FCF21.14EPS past 3/5Y42.80% —ROIC3.24%52W Low61.84 17.85%Perf 3Y5.73%
Dividend Est.0.36 (0.49%)EV/EBITDA14.21Sales past 3/5Y6.06% 8.77%Gross Margin56.45%Volatility1.86% 1.73%Perf 5Y-10.44%
Dividend TTM0.36 (0.49%)EV/Sales3.64EPS Y/Y TTM-39.53%Oper. Margin9.87%ATR (14)1.42Perf 10Y—
Dividend Ex-DateMay 06, 2026Quick Ratio1.30Sales Y/Y TTM7.81%Profit Margin5.92%RSI (14)73.28Recom2.54
Dividend Gr. 3/5Y17.60% —Current Ratio2.09EPS Q/Q10.53%SMA209.48%Beta0.85Target Price76.50
Payout26.38%Debt/Eq0.24Sales Q/Q8.74%SMA508.85%Rel Volume1.31Prev Close73.63
Employees25,000LT Debt/Eq0.22EarningsNov 10SMA2002.38%Avg Volume1.68MPrice72.88
IPO DateApr 09, 2019Option/ShortYes / YesEPS/Sales Surpr.12.33% 2.54%Net Debt/EBITDA1.36Volume2,199,132Change-1.02%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-02-26ReiteratedNeedhamBuy$107 → $98
Oct-27-26ReiteratedKeybancOverweight$91 → $84
Oct-12-26ReiteratedBTIGBuy$82 → $74
Oct-06-26InitiatedBarclaysEqual Weight$78 → $70
Sep-22-26ReiteratedJefferiesBuy$105 → $85
Aug-13-26ReiteratedBNP Paribas$79
Aug-12-26ReiteratedUBSBuy$91 → $35
Aug-12-26ReiteratedMizuhoOutperform$80 → $85
Aug-11-26ReiteratedBTIGBuy$100 → $82
Jul-15-26ReiteratedMizuhoOutperform$105 → $80
Latest News· Times ET
Oct-27-26
Oct-21-26
Oct-20-26
Oct-16-26
Oct-13-26
Oct-12-26
Oct-07-26
Sep-26-26
Sep-21-26
Sep-15-26
Sep-08-26
Sep-04-26
Company

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue10,80810,4019,9119,455—————
Cost of Goods Sold Incl. D&A4,7074,6564,3994,208—————
Gross Profit6,1015,7455,5125,247—————
Selling, General and Administrative Excl. Other3,5743,4493,2503,209—————
Research and Development1,426990876859—————
Other Operating Expense35-54-27140—————
Operating Income1,0671,3601,4131,039—————
Interest Expense208204186189—————
Unusual Expense
—————————
Non-Operating Income (Expense)-123429-18—————
Net Income Before Taxes7361,1601,256832—————
Income Taxes97180238-142—————
Consolidated Net Income6399801,018974—————
Net Income From Continuing Operations6399801,018974—————
Net Income6399801,018974—————
EPS (Recurring)1.301.992.061.98—————
EPS (Basic, Before Extraordinaries)1.301.992.061.98—————
EPS (Diluted)1.301.982.051.96—————
EBITDA2,7702,4952,6762,242—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio56.0639.8041.4139.86—————
Price To Sales Ratio3.283.754.234.07—————
Gross Margin56.4555.2455.6155.49—————
Operating Margin9.8713.0814.2610.99—————
Net Margin5.919.4210.2710.30—————
Shares Outstanding487495494493—————
Market Capitalization35,49339,01141,93638,513—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.